文献速递创伤与烧伤重症综合管理与镇静镇痛

全身给予一氧化碳释放分子-3保护猪骨筋膜室综合征模型的骨骼肌

Systemic Administration of Carbon Monoxide-Releasing Molecule-3 Protects the Skeletal Muscle in Porcine Model of Compartment Syndrome.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论猪骨筋膜室综合征模型中,切开减压时静脉给予一氧化碳释放分子-3(2 mg/kg)可改善微血管灌注、减轻组织损伤与凋亡并阻断全身白细胞活化。

本研究为临床前大动物实验,使用雄性约克夏-兰德瑞斯猪(50-60 kg),通过向右后肢前骨筋膜室灌注液体造成6小时骨筋膜室内压升高,随后切开减压并再灌注3小时。在切开减压时全身静脉给予一氧化碳释放分子-3(2 mg/kg)。结果显示,骨筋膜室综合征导致微血管灌注缺损(持续灌注毛细血管44%±1% vs 假手术组76%±4%,p<0.001)、组织损伤增加(溴化乙锭/双苯甲亚胺0.31±0.07 vs 假手术组0.17±0.03,p<0.05)、凋亡增加(体内荧光/双苯甲亚胺0.26±0.06 vs 假手术组0.13±0.03,p<0.05)及全身白细胞活化(14.7相对发光单位/10个多形核白细胞 vs 基线1.0±0.1,p<0.001)。给予一氧化碳释放分子-3后,持续灌注毛细血管增至68%±3%(p<0.001),组织损伤降至0.13±0.04(p<0.05),凋亡降至0.12±0.03(p<0.05),全身白细胞活化被阻断至3.9±0.3相对发光单位/10个多形核白细胞(p<0.001)。作者认为数据提示一氧化碳释放分子-3可能用于有骨筋膜室综合征风险的患者。

要点

  • 猪骨筋膜室综合征模型中,6小时骨筋膜室内压升高导致持续灌注毛细血管降至44%±1%(假手术组76%±4%,p<0.001)。
  • 切开减压时静脉给予一氧化碳释放分子-3(2 mg/kg)使持续灌注毛细血管升至68%±3%(p<0.001)。
  • 该处理使组织损伤指标溴化乙锭/双苯甲亚胺降至0.13±0.04(未处理骨筋膜室综合征组0.31±0.07,p<0.05)。
  • 该处理使凋亡指标体内荧光/双苯甲亚胺降至0.12±0.03(未处理组0.26±0.06,p<0.05)。
  • 该处理阻断全身白细胞活化至3.9±0.3相对发光单位/10个多形核白细胞(未处理组14.7,基线1.0±0.1,p<0.001)。

适用人群与场景

  • 雄性约克夏-兰德瑞斯猪,体重50-60 kg,用于临床前大动物骨筋膜室综合征模型。

处置流程与药物剂量

  • 通过向右后肢前骨筋膜室灌注液体造成6小时骨筋膜室内压升高。
  • 切开减压时全身静脉给予一氧化碳释放分子-3,剂量2 mg/kg。
  • 给药后继续再灌注3小时。

研究设计与关键结果

  • 研究类型为动物实验,样本为雄性约克夏-兰德瑞斯猪(50-60 kg)。
  • 骨筋膜室综合征组持续灌注毛细血管44%±1% vs 假手术组76%±4%(p<0.001)。
  • 骨筋膜室综合征组组织损伤(溴化乙锭/双苯甲亚胺)0.31±0.07 vs 假手术组0.17±0.03(p<0.05)。
  • 骨筋膜室综合征组凋亡(体内荧光/双苯甲亚胺)0.26±0.06 vs 假手术组0.13±0.03(p<0.05)。
  • 骨筋膜室综合征组全身白细胞活化14.7相对发光单位/10个多形核白细胞 vs 基线1.0±0.1(p<0.001)。
  • 一氧化碳释放分子-3组持续灌注毛细血管68%±3%(p<0.001),组织损伤0.13±0.04(p<0.05),凋亡0.12±0.03(p<0.05),全身白细胞活化3.9±0.3相对发光单位/10个多形核白细胞(p<0.001)。

证据类型、等级与局限

  • 证据类型:动物实验(临床前大动物模型)。
  • 作者结论:切开减压时给予一氧化碳释放分子-3可保护对抗骨筋膜室综合征诱导的微血管灌注缺损、组织损伤和全身白细胞活化;数据提示其可能用于有骨筋膜室综合征风险的患者。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,一氧化碳释放分子-3可能用于有骨筋膜室综合征风险的患者,该结论来自猪模型。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Acute limb compartment syndrome, a complication of musculoskeletal trauma, results in muscle necrosis and cell death. Carbon monoxide, liberated from the carbon monoxide-releasing molecule-3, has been shown protective in a rat model of compartment syndrome. The purpose of this study was to test the effect of carbon monoxide-releasing molecule-3 in a preclinical large animal model of compartment syndrome, with the ultimate goal of developing a pharmacologic adjunct treatment for compartment syndrome.

DESIGN: Animal research study.

SETTING: Basic research laboratory in a hospital setting.

SUBJECTS: Male Yorkshire-Landrace pigs (50-60 kg).

INTERVENTIONS: Pigs underwent 6 hours of intracompartmental pressure elevation by infusing fluid into the anterior compartment of the right hind limb. Carbon monoxide-releasing molecule-3 was administered systemically (2 mg/kg, IV) at fasciotomy, followed by 3-hour reperfusion.

MEASUREMENTS AND MAIN RESULTS: Muscle perfusion, inflammation, injury, and apoptosis were assessed in the skeletal muscle. Systemic leukocyte activation was assessed during compartment syndrome and reperfusion. Elevation of hind limb intracompartmental pressure resulted in significant microvascular perfusion deficits (44% ± 1% continuously perfused capillaries in compartment syndrome vs 76% ± 4% in sham; p < 0.001), increased tissue injury (ethidium bromide/bisbenzimide of 0.31 ± 0.07 in compartment syndrome vs 0.17 ± 0.03 in sham; p < 0.05), apoptosis (fluorescence in vivo/bisbenzimide of 0.26 ± 0.06 in compartment syndrome vs 0.13 ± 0.03 in sham; p < 0.05), and systemic leukocyte activation (14.7 relative luminescence units/10 polymorphonuclear leukocytes in compartment syndrome vs 1.0 ± 0.1 in baseline; p < 0.001). Systemic application of carbon monoxide-releasing molecule-3 at fasciotomy increased the number of continuously perfused capillaries (68% ± 3%; p < 0.001), diminished tissue injury (ethidium bromide/bisbenzimide of 0.13 ± 0.04; p < 0.05), apoptosis (fluorescence in vivo/bisbenzimide of 0.12 ± 0.03; p < 0.05), and blocked systemic leukocyte activation (3.9 ± 0.3 relative luminescence unit/10 polymorphonuclear leukocytes; p < 0.001).

CONCLUSIONS: Administration of carbon monoxide-releasing molecule-3 at fasciotomy offered protection against compartment syndrome-induced microvascular perfusion deficit, tissue injury, and systemic leukocyte activation. The data suggest the potential therapeutic application of carbon monoxide-releasing molecule-3 to patients at risk of developing compartment syndrome.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bihari A, Cepinskas G, Sanders D, et al. Systemic Administration of Carbon Monoxide-Releasing Molecule-3 Protects the Skeletal Muscle in Porcine Model of Compartment Syndrome. Crit Care Med. 2018. PMID: 29384781. doi:10.1097/CCM.0000000000002998

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。